Comparison of Polynucleotide, Sodium Hyaluronate, and Crosslinked Sodium Hyaluronate for the Management of Painful Knee Osteoarthritis: A Multi-Center, Randomized, Double-Blind, Parallel-Group Study. Issue 5 (18th October 2022)

• Record Type: Journal Article
• Authors: Moon, Jee Youn; Kim, Jeongsoo; Lee, Jin Young; Ko, Youngkwon; Park, Hue Jung; Jeon, Young Hoon
• Is Part Of: Pain medicine. Volume 24:Issue 5(2023)
• Page Start: 496
• Page End: 506
• Publication Date: 2022-10-18
• Subjects: Crosslinked Sodium Hyaluronate -- Intra-Articular Injection -- Knee Osteoarthritis -- Polynucleotide Sodium -- Sodium Hyaluronate; Pain -- Periodicals; Pain -- Treatment -- Periodicals; Analgesics -- Periodicals; Pain -- Periodicals; Pain Management -- Periodicals; Douleur -- Périodiques; Douleur -- Traitement -- Périodiques; Analgésiques -- Périodiques; Analgésique; Soulagement de la douleur; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.047205
• DOI: 10.1093/pm/pnac155
• Languages: English
• ISSNs: 1526-2375

Abstract

Abstract: Objective: To compare the clinical effectiveness of sodium polynucleotide, classic hyaluronic acid, and crosslinked hyaluronic acid for the management of painful knee osteoarthritis. Design: Randomized, double-blind, parallel-group clinical trial. Setting: Multicenter study. Subjects: Patients with chronic painful knee osteoarthritis. Methods: Ninety patients were selected and randomized into polynucleotide, classic hyaluronic acid, and crosslinked hyaluronic acid groups (30 per group). Intra-articular injections of the viscosupplement for each group were administered to the patients three times at one-week intervals. The primary outcome was differences in changes of weight-bearing pain scores at 16 weeks between the groups. The secondary outcomes were changes in the intensity of knee pain during weight-bearing, walking, and rest, and functional disability, quality of life, and adverse events during the 16-week follow-up period. Results: At 16 weeks, the polynucleotide group showed a higher reduction in pain score using a Visual Analog Scale score (0–100) than the classic hyaluronic acid (−17.6 [95% CI = −35.1 to −0.1]; P = .048) and crosslinked hyaluronic acid (−22.4 [95% CI = −41.5 to −3.3]; P = .016) groups. The polynucleotide and crosslinked hyaluronic acid groups showed an early-onset reduction in knee pain during weight-bearing, walking, and rest. All three groups showed reductions in functional disability and improved quality of life at 16 weeks without inter-group differences. No severe adverse events were reported throughout the study period. Conclusion: Polynucleotide significantly relieves pain more and relieves pain faster in patients with knee osteoarthritis than classic and crosslinked hyaluronic acid, with improved health-related quality of life.